Enrichment of Adipose-derived Mesenchymal Stem Cells Using Resveratrol by Erdman, Christopher Paul
Enrichment of Adipose-derived Mesenchymal Stem Cells Using 
Resveratrol
A Thesis Presented to the Academic Faculty
by
Christopher Paul Erdman
In Partial Fulfillment of Institute Requirements
for the Bachelor Degree of Science of Biomedical Engineering
with Thesis Option
Department of Biomedical Engineering
Georgia Institute of Technology
May 2009





 Barbara D. Boyan, Ph. D.
 Department of Biomedical Engineering
 Georgia Institute of Technology
 Robert Guldberg
 Department of Mechanical Engineering
 Georgia Institute of Technology
   
      Date Approved: 4/30/2009
Table of Contents
1.  Summary 1
2.  Introduction 2
3.  Results 6
4.  Discussion 10
5.  Conclusion 12
6.  Experimental Procedures 13
6.1 ADMSC Differentiation Verification 13
6.2 Physiological Response of rat MSCs 15
6.3 Effect of Resveratrol on Human ADMSCs 17
6.4 Statistical Analysis 17
7.  Acknowledgements 18
8.  References 19
9.  Figures 22
i
1.  Summary
 Mesenchymal stem cells (MSCs) hold great promise for the application of tissue 
engineering to orthopedic problems such as critical-size defects.  Cell sorting has 
indicated a benefit to enriching the MSC population, but is undesired for clinical 
applications.  Pharmacological enrichment utilizing adipogenic inhibitors such as 
resveratrol represent a clinically viable alternative.  Cells were isolated from rats, and 
treated with differentiation media to verify multipotency, and were then treated with 0, 
12.5, and 25 µM resveratrol in growth media and osteogenic media.  MSC and 
osteoprogenitor (OPC) populations were measured using flow cytometry and OPC 
quality  was assessed with osteocalcin production, osteoprotegerin production, and 
alkaline phosphatase activity.  Resveratrol increased the population percent and cell 
number of MSCs in both growth and osteogenic media, but only increased the number 
of OPCs in growth media.  In both media types resveratrol increased alkaline 
phosphatase activity  and osteocalcin levels.  Resveratrol enriches ADMSCs for 
mesenchymal stem cells and osteoprogenitors. 
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2.  Introduction
 The repair of large bone defects is one of the major problems currently facing 
orthopedics.  The two current treatments are autografts and allografts [1].  Both 
treatment options have numerous problems and complications.  Autografts suffer from a 
limited supply  of tissue and insufficient structural integrity.  Allografts have the 
advantage of providing structural integrity, but only  in the short-term, and have a high 
failure rate.  The lack of an effective treatment option is due largely to the inability of the 
graft to effectively integrate with the patientʼs existing bone and to revascularize [2]. 
Stem cell therapy has the potential to provide a solution in healing large bone defects.
 Stem cells are a type of cell with the capabilities of self-renewal and multipotency. 
An important group of stem cells is mesenchymal stem cells (MSCs).  These cells have 
the ability to differentiate into many tissue pathways such as osteogenic, chondrogenic, 
and adipogenic.  Their multipotency and ability  to avoid allogeneic rejection make them 
a prime candidate for tissue engineering [3].  The traditional source of MSCs is bone 
marrow, which are typically defined as (a) able to adhere to plastic; (b) exhibiting the 
following surface marker phenotype:  CD14-, CD19-, CD34-, CD45-, HLA-DR-, CD73+, 
CD90+, CD105+; and (c) capable of multipotent differentiation [4].  More recently CD271 
has been detected on bone marrow-derived MSCs, and has been proposed as a marker 
for their isolation [5, 6].  Their clinical isolation has been accompanied with a number of 
adverse events such as morbidity, pain, and low yield.  These complications, particularly 
the low yield, highlight the need for research into the characterization of new sources for 
MSCs.
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 Adipose tissue has been shown to contain a supply of multipotent progenitor 
cells, called adipose-derived mesenchymal stem cells (ADMSCs), capable of maturing 
along the connective tissue lineages [7-9].  It has been shown to yield more stem cells 
per tissue amount than bone marrow [10].  The phenotype of ADMSCs has been 
described in the literature, indicating many similarities with bone marrow-derived MSCs 
as described above; particularly CD34-, CD45-, CD73+, CD90+, and CD271+ [11-18].
 Along with mesenchymal stem cells, adipose tissue also yields a variety of other 
cells such as preadipocytes, osteoprogenitor cells, vascular smooth muscle cells, and 
vascular endothelial cells [10].  Thus far no clear phenotype of osteoblast and 
osteoprogenitor surface markers has been developed.  Osteocytes, but not osteoblasts 
have been shown to selectively express E11, making it a potential late-stage osteogenic 
marker [19].  Osteocalcin (OCN), although not typically thought of as a surface marker, 
has been used previously as such to detect circulating osteoblasts from the bone 
marrow [20].  Finally α-smooth muscle actin has been shown to identify circulating 
osteoprogenitor cells following osteoblast ablation [21].
 In order to effectively utilize ADMSCs clinically, the undesired cells need to be 
separated from the mesenchymal stem cells and desired progenitors [22, 23].  A 
number of groups are currently looking at a variety of ways to increase the overall 
multipotency of this heterogeneous population, or to enrich the stem cells.  The current 
technique is to use fluorescent activated cell sorting (FACS) to sort the cells based on 
the presence of certain surface markers associated with mesenchymal stem cells [22, 
24-26].
Stem Cell Enrichment                                                                                                           Erdman 3 of 30
 The use of FACS to enrich MSCs poses a couple of problems to clinical use. 
First, FACS requires the use of animal derived antibodies.  These antibodies are 
expensive and pose a concern for clinical use in that they could elicit a adverse reaction 
in the patient.  Secondly, when using the FACS technique sterility  can be difficult to 
maintain, and infected cell grafts could ruin a tissue engineered implant.
 The differentiation of these cells is determined by many factors including local 
environment and chemical signals, and hormones [27, 28].  A reciprocal relationship 
exists between osteogenesis and adipogenesis; thus inhibition of one leads to activation 
of the other.  It has recently been shown that resveratrol and isonicotinamide enhance 
osteogenesis, and nicotinamide enhances adipogenesis through inhibition and 
activation of Sirt1 [29].  
 A pharmacological approach could solve all of the problems posed by FACS 
enrichment.  Specifically, the use of resveratrol as an adipogenic inhibitor could provide 
an inexpensive and effective pharmacological means to enrich mesenchymal stem 
cells, and to select for the desired progenitors.  Successful pharmacological enrichment 
of ADMSCs for osteoprogenitors could potentially provide a novel treatment for critical 
sized bone defects and regenerative medicine.
 The project aims to accomplish:  (i) the verification of a protocol to isolate 
mesenchymal stem cells from adipose tissue, (ii) the establishment of an adipose-
derived stem cell model for further study in bone regeneration and engineering, and (iii) 
the investigation of resveratrol as a pharmacological enriching agent for adipose-
derived mesenchymal stem cells and osteoprogenitors.
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 In order to verify an isolation protocol for MSCs from adipose tissue, we 
differentiated the cells with adipogenic media (AM), chondrogenic media (CM), and 
osteogenic media (OM) and assessed the presence of differentiation markers for each 
treatment.  To establish an ADMSC model, we defined two populations of interest: 
mesenchymal stem cells (MSCs) and osteoprogenitor cells (OPCs).  MSCs were 
defined as CD 271+, CD 73+, and CD 45-.  OPCs were defined as E11+ and OCN+.  The 
potential of resveratrol as an enriching agent was assessed by treating isolated rat 
ADMSCs with 0, 12.5, and 25 µM resveratrol, and measuring the population changes of 
MSCs, OPCs, and the increase of the osteogenic markers:  osteocalcin, 
osteoprotegerin, and alkaline phosphatase activity.
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3.  Results
Verification of Multipotency
 Adipose tissue has been shown to yield a population of multipotent mesenchymal 
stem cells.  In order to verify  the multipotency of the isolated cell population, rat 
ADMSCs were differentiated into osteoblasts (Figure 1), adipocytes (Figure 2), and 
chondrocytes (Figure 3).  After 14 days, cells treated with osteogenic media (OM) 
showed phosphate deposition (Figure 1a).  Osteogenic media significantly  increased 
alkaline phosphatase activity over growth media (GM) throughout a 28 day induction. 
Additionally, the cells grown in GM showed little increase in activity. Activity  peaked at 
the release over 40 nMol/mg Prot./min of phosphate in the osteogenic group (Figure 
1b).  Throughout differentiation, ADMSCs expressed Runx2, alkaline phosphatase, and 
osteopontin (Figure 1c).
 After 14 days of treatment in adipogenic media (AM), ADMSC stained positive for 
lipid accumulation (Figure 2a).  Adipogenic media increased adiponectin levels 
throughout a 28 day  treatment, over cells grown in GM (Figure 2b), which showed no 
significant change in adiponectin levels.  Adiponectin levels peaked at just under 100 
pg/105 cells.  ADMSCs expressed leptin, peaking after 14 days, and PPARγ2 during 
adipogenic differentiation (Figure 2c).
 Adipose-derived mesenchymal stem cells treated with chondrogenic media (CM) 
stained positive for proteoglycan production (Figure 3a).  ADMSCs grown in 
chondrogenic media expressed collagen I, collagen II, aggrecan, and collagen X. 
Collagen I expression was present throughout the entire 21 day differentiation of the 
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cells.  Expression of collagen II and aggrecan began after 14 days in culture, where as 
collagen X expression appeared after 21 days (Figure 3b).
Dose Determination and Effect on Osteogenic Markers
 In order to determine the proper concentration range, ADMSCs were treated with 
0, 12.5, 25, and 50µM resveratrol in GM and OM.  In GM, cell number varied 
significantly in each treatment with respect to the control (Figure 4a).  The lowest 
treatment increased cell number from 4.5 x 105 to 5.0 x 105 cells.  Treatments of 25 and 
50µM resveratrol reduced cell number to 4.1 an 0.2 x 105 cells respectively.  In OM, cell 
number again varied little across the concentrations.  Resveratrol increased alkaline 
phosphatase activity in a dose-dependent manner in both media types through 25µM, 
peaking at 9 nMol Pi/mg Prot./min for GM and 23 nMol Pi/mg Prot./min in OM.  The 
50µM treatment increased activity significantly in GM and OM to 2 and 6 nMol Pi/mg 
Prot./min respectively (Figure 4b).
 Adipose-derived mesenchymal stem cells treated with resveratrol increased 
levels and activity of certain osteogenic markers such as osteoprotegerin, osteocalcin, 
and alkaline phosphatase activity.  Resveratrol increased osteoprotegerin levels in GM 
dose-dependently, but showed no change in OM (Figure 5a).  Resveratrol slightly 
increased osteocalcin levels over control in both media types (Figure 5b).  The 
treatment increased alkaline phosphatase activity in GM and OM in a dose-dependent 
manner (Figure 5c and 5d).
 Resveratrol treatment improved osteogenic cell morphology (Figure 6).  Growth 
media vehicle-control cells (Figure 6a) exhibited a fibroblastic morphology typical of 
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mesenchymal stem cells, excepting for the lipid vacuoles present in many of the cells. 
In osteogenic media, vehicle control cells (Figure 6b) exhibited a spread morphology 
with a few cells developing lipid vacuoles.  Cells treated with 25µM resveratrol in GM 
(Figure 6c) had a morphology in between both vehicle controls.  Most cells had a 
fibroblastic shape, but many were more spread, resembling the OM vehicle control. 
Cells treated with 25µM resveratrol in OM (Figure 6d) had a more compacted 
morphology and appeared to be developing nodules.  In both GM and OM 25µM 
resveratrol (Figures 6c and 6d respectively) reduced lipid accumulation relative to the 
vehicle controls (Figure 6a and 6b respectively).
Resveratrol Enriches ADMSCs for MSCs and OPCs
 Resveratrol treatment enriched the MSC  and osteoprogenitor (OPC) populations 
in cultured ADMSC.  Treatment with resveratrol increased the number of MSCs in both 
GM and OM, with the 25µM groups showing a significant increase over the 12.5µM 
groups.  In GM resveratrol treatment increased the cell number by  5-fold, and in OM by 
2-fold (Figure 7a).  Population percentage showed a similar trend as the cell numbers, 
except that the two media types showed little difference, with 4-fold and 2-fold increases 
in GM and OM respectively (Figure 7b).
 In addition to enriching the MSC population, resveratrol treatment enriched the 
population of OPCs.  The number of OPCs increased significantly with resveratrol 
treatment in GM, with a 3-fold increase at the highest dose.  The treatment had no effect 
on the number of OPCs in OM.  However, OM significantly increased the number and 
population percent of OPCs over that of  GM in nearly every group  (Figure 8a).  Similar 
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results were seen in terms of population percentage of OPCs.  Treatment increased the 
percent of OPCs in GM, with a 2-fold increase at the highest dose.  Resveratrol had no 
effect on the percent of OPCs in OM, however (Figure 8b).
Effect of Resveratrol on Human ADMSCs
 In order to examine the effect of resveratrol on human ADMSCs and determine 
an appropriate concentration range, cells were isolated from donated human adipose 
tissue, and treated with 0, 12.5, 25, 50, and 100 µM resveratrol.  Resveratrol increased 
alkaline phosphatase activity in GM at 12.5µM.  Higher concentrations decreased 
activity  below the control.  In OM, resveratrol increased alkaline phosphatase activity 
dose-dependently to a maximum at 50µM.  The highest dose showed activity similar to 
control (Figure 9a).  In both GM and OM, resveratrol treated cells showed a reduced cell 
number, and altered cell morphology  (Figure 9d and 9e).  Human ADMSCs grown in 
0µM + GM showed a good MSC  morphology, and were near confluent after 7 days 
(Figure 9b).  Those treated with 100µM resveratrol however, exhibited an elongated 
morphology with many dendritic appendages stretching across the plate.  These cells 
not proliferate as well, and there were markedly fewer cells than the vehicle control 
(Figure 9d).  Treatment with resveratrol-free osteogenic media exhibited an osteoblastic 
phenotype (Figure 9c).  These cells too proliferated well and were confluent after 7 
days.  Similar to their GM counterpart, the cells treated with 100µM resveratrol showed 
a rather dendritic phenotype, and had a reduced cell number (Figure 9e).
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4.  Discussion
 Mesenchymal stem cells hold great promise for the application of tissue 
engineering to orthopedic problems such as critical-size defects.  Unfortunately 
significant problems must be solved before there can be widespread application of stem 
cell therapies, such as timely, safe, and cost-effective means of ensuring the desired 
cellular differentiation and tissue regeneration.  Enrichment through cell sorting has 
posed a promising technique to ensure the proper differentiation of MSCs, but carries 
with it a host of problems including expense, potential for adverse reactions, and 
difficulty in maintaining sterility.  With regards to orthopedic applications, adipogenic 
inhibitors, such as resveratrol, present a unique opportunity  for the development of a 
pharmacological enrichment for both medical therapies and further inquiry.
 Resveratrol treatment has been shown to provide a potent enrichment for MSCs 
and OPCs.  It increases the number and percentage of MSCs in both media types, 
thereby enriching the MSC population.  Resveratrol increased the number and 
percentage of OPCs in GM only, and had no effect in OM.  Even though resveratrol had 
no effect on the OPC population in OM, there were generally more OPCs in each OM 
group than GM group.  The differences between media types are likely  due to the effect 
of the differentiation media.  The dexamethasone in the OM is likely pushing the cells to 
become osteoblasts so strongly that it overshadows the resveratrol effect.  These 
results suggest that an improved enrichment would begin with resveratrol in GM to 
elevate the number of MSCs, followed by treatment with OM to push them to 
differentiate.
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 Although osteocalcin levels did not vary significantly, osteoprotegerin did 
increase slightly in GM.  Since alkaline phosphatase activity increased in both media 
types and the treatment lasted 7 days, the cells are likely in the early stages of 
osteogenesis, and may not have begun significant production of osteocalcin and 
osteoprotegerin.
 The isolation method of ADMSCs has been tailored to isolate only adherent 
stromal cells, and to avoid any fibroblast contamination.  The alkaline phosphatase 
results initially indicate a different optimum concentration for each media.  The cell 
culture images suggest a different story.  In this particular case, the donor tissue was 
mammarian, which did not initially  pose any cause for concern.  During the treatment, 
most notably  at the higher concentrations, the cells lost the fibroblastic morphology 
typical to MSCs, and took on a more elongated morphology with numerous dendritic 
appendages.  Moreover, the cells treated with 100µM resveratrol appeared to have 
more in common than their 0µM counterparts in that they had the same morphology  and 
showed similar growth.  Further examination suggested that these may be mammarian 
epithelial cells.  These cells are found in the stroma of the tissue, and may be an 
unavoidable contaminant from this tissue.
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5.  Conclusion
 Enrichment of mesenchymal stem cells has been shown to increase their 
effectiveness in tissue repair and regeneration.  Resveratrol enriches adipose-derived 
mesenchymal stem cells for both MSCs and OPCs by increasing the overall number 
and percentage of total cells.  Current theories indicate that different donor sites may 
yield differing qualities of cells.  Our results with human ADMSCs indicate that this is 
very  likely the case and that certain tissues may present undesirable and unavoidable 
contaminants, making them undesirable for certain applications.
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6.  Experimental Procedures
6.1 ADMSC Differentiation Verification
 Cell Isolation and Culture:  Inguinal fat pads, subcutaneous fat surrounding the 
thigh, were harvested from 100 - 125g sprague dawley rats according to approved 
IACUC protocol.  The tissue was washed three times in Hankʼs Balanced Saline 
Solution (HBSS), and digested in trypsin for 30 minutes at 37 ˚C.  The tissue was then 
cut into smaller pieces and digested in collagenase IA  (9125 units) and dispase (75 
units) until completely digested.  The upper layer of adipocytes was removed, and the 
cell suspension was filtered through a 40µm cell strainer.  The digestion was quenched 
with GM (Lonza, Basel, Switzerland) and the cells were pelleted (2000 g for 10 
minutes).  The cells were plated at 5,000 cells/cm2 and washed with phosphate buffered 
saline (PBS) after 24 and 48 hours.  Cells were grown in 24 or 6 well plates in growth 
media (GM), adipogenic media (AM), osteogenic media (OM) and chondrogenic media 
(CM) for 7, 14, 21, and 28 hours.
 Adipocyte Staining with Oil Red O:  Samples were washed twice with PBS, and 
fixed with 10% formalin.  They were then stained with a 0.3% Oil Red O/0.4% dextrin 
solution for 20 minutes.  The cells were rinsed in running water, counterstained with Gill 
II hematoxylin, and rinsed with distilled water.  They were blued in Scottʼs solution, and 
imaged via light microscopy.
 Adiponectin:  Twenty-four hours prior to harvest, cell culture media were replace 
with fresh media.  At harvest, cell culture media were removed and stored at -20˚C.  Cell 
monolayers were trypsinized for 10 minutes to remove the cells.  The reaction was 
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quenched with full medium, and the cells were centrifuged (2000 g for 10 minutes) and 
resuspended in PBS.  Cells were counted, resuspended in 0.05% Triton-X 100, and 
stored at -20˚C.  After the harvest of all groups, cell media were thawed, and 
adiponectin levels were measured via adiponectin ELISA (R&D Systems Minneapolis, 
MN).
 Von Kossa Phosphate Deposition Staining:  Samples were washed twice with 
PBS, and fixed with 10% formalin.  On the day of the staining, they were rehydrated to 
distilled water and stained in 5% silver nitrate for 20 minutes under UV light.  The 
samples were rinsed in distilled water, and stained in 5% sodium thiosulfate for 3 
minutes.  They were washed with distilled water and counterstained for 5 minutes with 
nuclear-fast red.  Samples were washed again in water and imaged via light 
microscopy.
 Alkaline Phosphatase Activity:  Cell monolayers were lysed with 0.05% Triton-X 
100 and stored at -20˚C until assay date.  Alkaline phosphatase activity was measured 
as the release p-nitrophenol from p-nitrophenolphosphate.  Activity was normalized to 
protein concentration and reaction duration.
 Proteoglycan Staining with Toluidine Blue:  Samples were washed twice with 
PBS and fixed in 10% formalin.  On the day of staining, they  were rehydrated to distilled 
water and stained in 0.1% toluidine blue solution for 5 minutes.  The samples were 
washed in distilled water and imaged via light microscopy.
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 Gene Expression:  ADMSCs were grown in 6 well plates treated with AM, OM, 
GM, and CM for 7, 14, and 21 days.  On the day of the harvest, cell media were 
aspirated, and RNA was isolated with a trizol-chloroform extraction.  Samples were then 
converted into cDNA using random primers.  Samples were then analyzed via PCR for 
the presence of runx2, alkaline phosphatase, osteopontin, leptin, PParγ2, collagen I, 
collagen II, aggrecan, collagen X, and GapDH.
6.2 Physiological Response of rat MSCs
 Cell Isolation and Culture:  Cells were isolated as described above.  The cells 
were grown in T-75 flasks and 24 well plates for 7 days in GM and OM supplemented 
with 0, 12.5, or 25µM resveratrol.
 Dose Determination:  ADMSCs were grown in 24 well plates in GM and OM 
supplemented with 0, 12.5, 20, 50µM resveratrol for 7 days.  On the day of the harvest, 
cell monolayers were trypsinized for 10 minutes to remove the cells.  The reaction was 
quenched with full medium, and the cells were centrifuged (2000 g for 10 minutes) and 
resuspended in PBS.  Cells were counted, resuspended in 0.05% Triton-X 100, and 
stored at -20˚C.  Alkaline phosphatase activity was measured as described above.
 Cell Morphology:  Every 24 hours, an image of each group  was captured via light 
microscopy.
 Flow Cytometry:  Cells were washed with PBS, detached with 0.25% trypsin, and 
pelleted by centrifugation (2000 g for 10 minutes).  The cells were counted, and 500,000 
cells were aliquoted for flow cytometry.  The cells were washed with the wash buffer 
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from the BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit (BD Franklin 
Lakes, NJ).  The cells for MSC measurement were incubated with antibodies for CD 271 
(Santa Cruz Biotechnology Santa Cruz, CA), CD 73 (BD Franklin Lakes, NJ), CD 45 
(BD Franklin Lakes, NJ), and an Allophycocyanin conjugated Goat anti-Mouse 
secondary antibody (R&D Systems Minneapolis, MN).  The cells for OPC measurement 
were incubated with antibodies for osteocalcin (Santa Cruz Biotechnology Santa Cruz, 
CA), E11 (Sigma St. Louis, MO), a FITC  conjugated anti-Rabbit secondary antibody 
(ABCam Cambridge, MA), and an Allophycocyanin conjugated Donkey anti-Goat 
secondary antibody (R&D Systems Minneapolis, MN) in 1% bovine serum albumin in 
PBS for 20 minutes.  In between incubations the cells were washed twice.  Populations 
were then measured on a BD LSR Flow Cytometer relative to isotype control.
 Osteogenic Differentiation Markers:  Twenty four hours prior to harvest, cell 
medium was replaced with fresh medium.  This medium was collected, and the cells 
were lysed with 0.05% Triton-X 100.  Alkaline phosphatase activity was measured as 
the release p-nitrophenol from p-nitrophenolphosphate.  Osteocalcin levels in the 
conditioned media were measured via the Human Osteocalcin Radioimmunoassay kit 
(Biomedical Technologies Stoughton, MA) as reported previously.  Osteoprotegerin 
levels in the conditioned media were measured via the Osteoprotegerin ELISA (R&D 
Systems Minneapolis, MN).
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6.3 Effect of Resveratrol on Human ADMSCs
 Cell Isolation and Culture:  Human adipose tissue was donated during a breast 
reduction following an approved IRB protocol.  After receipt of the tissue, ADMSCs were 
isolated as described above.
6.4 Statistical Analysis
 Data were analyzed with a one-way ANOVA to determine the presence of 
significant differences between groups.  If the ANOVA yielded alpha ≤ 0.05, a t-test was 
used with a bonferroniʼs modification was used to determine significance.  Adiponectin 
levels, surface characterization, total cell number, and alkaline phosphatase activity with 
resveratrol represent a mean of three ± standard error.  All symbols represent α ≤ 0.05 
(# with respect to same timepoint, ● relative to next lowest treatment, and *  with respect 
to vehicle control).  Induction alkaline phosphatase activity, osteoprotegerin levels, and 
osteocalcin levels represent a mean of 6 ± standard error.
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9.  Figures
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Figure 1:  Adipose-derived Mesenchymal Stem Cells Differentiate into Osteoblasts
ADMSCs were grown for 14 days in OM, and showed positive for phosphate deposition via Von 
Kossa staining (a).  ADMSCs showed increased alkaline phosphatase activity over 28 days of 
induction in OM.  Cells grown in GM showed little change in alkaline phosphatase activity (b). 
ADMSCs treated with OM expressed Runx2, ALP (alkaline phosphatase), and OPN (Osteopontin) 
throughout a 21 day induction (c).  Alkaline phosphatase activity data represent mean ± standard 
error (n = 6).  Data were analyzed with a one-way ANOVA followed by a two-tailed t-test with a 
bonferroniʼs modification (# represents α ≤ 0.05 with respect to same time point control).
(a) (b)
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(a) (b)
(c)
Figure 2:  Adipose-derived Mesenchymal Stem Cells Differentiate into Adipocytes
ADMSCs were grown for 14 days in AM, and showed positive for lipid accumulation via Oil Red O 
staining (a).  ADMSCs showed increased adiponectin levels over 28 days of induction in AM.  Cells 
grown in GM showed little change in adiponectin levels (b).  ADMSCs treated with AM expressed 
Leptin, and PPARγ2 throughout a 21 day induction (c).  Adiponectin data represent mean ± 
standard error (n = 3).  Data were analyzed with one-way ANOVA followed by a two-tailed t-test 
with a bonferroniʼs modification (# represents α ≤ 0.05 with respect to same time point control).

















Figure 3:  Adipose-derived Mesenchymal Stem Cells Differentiate into Chondrocytes
ADMSCs were grown for 14 days in CM, and showed positive for proteoglycan production via toluidine 
blue staining (a).  ADMSCs treated with CM expressed Collagen I, Collagen II, Aggrecan, and 
Collagen X throughout a 21 day induction (b).
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Figure 4:  Determination of Dose
Resveratrol had no effect on cell number in either GM or OM up to 50 µM (a).  At 50 uM, 
resveratrol reduced cell number significantly.  Alkaline phosphatase activity increased 
dose-dependently up  to 50 µM, at which point it decreased below baseline (b).  Values 
represent mean ± sem (n = 3).  Data were analyzed with a one-way ANOVA follwed by a 
two-tailed t-test with a bonferroniʼs modification (● represents α ≤ 0.05 with respect to 
same time point control and * represents α ≤ 0.05 with respect to vehicle control).
(a)
(b)
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Figure 5:  Resveratrol increases Osteogenic Markers
Resveratrol increased levels of secreted osteoprotegerin in a GM.  In OM resveratrol had no 
effect on osteoprotegerin levels and for all treatments values were lower than their 
corresponding GM group  (a).  Treatment with resveratrol increased osteocalcin levels over 
vehicle-control in both GM and OM.  There was no difference in osteocalcin levels between 
the two media conditions (b).  Treatment increased alkaline phosphatase activity in GM and 
OM (c).  Values represent mean ± sem (n = 6).  Data were analyzed with a one-way ANOVA 
followed by a two-tailed t-test with a bonferroniʼs modification (* represents α ≤ 0.05 with 




Stem Cell Enrichment                                                                                                           Erdman 27 of 30
Figure 6:  Resveratrol Enhances Osteogenic Morphology
ADMSCs grown in GM (a, c) and OM (b, d) exhibit a markedly different morphology.  ADMSCs in GM 
with no resveratrol had fibroblastic morphology (a), whereas those in OM without resveratrol (b) had a 
more spread morphology.  Cells treated with 25µM resveratrol in GM seemed to show a mix between 
the fibroblastic and spread morphology (c).  ADMSCs treated with OM and 25µM resveratrol show a 
more compacted morphology, and appeared to be developing nodes.  Additionally, both GM vehicle 
control cells (a) and OM vehicle control cells (b) showed the development of lipid vacuoles in many 
cells, whereas those treated with 25µM resveratrol showed reduced lipid accumulation (c, d).
(a) (b)
(c) (d)
Figure 7:  Resveratrol Enriches the MSC Population in ADMSCs
MSCs were defined as CD 271+, CD73+, and CD 45-.  Resveratrol treatment increased the 
number of MSCs in a dose-dependent manner in both GM and OM.  In both treatments, the 
number of MSCs was greater in GM than in OM (a).  Resveratrol increased the MSC population 
percentage in a dose-dependent manner in both media types.  In terms of percent of total cell 
population, there was little difference between the media conditions in both treatments (b). 
Values represent mean ± sem (n = 3).  Data were analyzed with a one-way ANOVA follwed by a 
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(a)
(b)
Figure 8:  Resveratrol Enriches the OPC Population in ADMSCs
OPCs were defined as OCN+ and E11+.  Resveratrol treatment increased the number of OPCs in GM. 
It had no effect on the number of OPCs in OM.  In all treatments, the number of OPCs was greater in 
OM than in GM (a).  Resveratrol increased the OPC population percentage in GM.  It had no effect on 
the population percent in OM, which was significantly greater than all GM samples (b).  Values 
represent mean ± sem (n = 3).  Data were analyzed with a one-way ANOVA followed by a two-tailed t-
test with a bonferroniʼs modification (● represents α ≤ 0.05 with respect to 12.5µM group and # 
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(a)
Figure 9:  Effect of Resveratrol on Human ADMSCs
Resveratrol increased activity of alkaline phosphatase in both GM and OM, but peaked at different 
doses.  In GM 12.5µM induced the highest activity, while in OM 50uM caused the highest activity 
(a).  Resveratrol reduced the number of cells in both GM (b, d) and OM (c, e).  Cells treated with 
100µM resveratrol (d, e) exhibited a more elongated and dendritic morphology than vehicle 
control groups (b, c).  Values represent mean ± sem (n = 6).  Data were analyzed with a one-way 
ANOVA follwed by a two-tailed t-test with a bonferroniʼs modification (* represents α ≤ 0.05 with 
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